Compare CRL & OBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRL | OBDC |
|---|---|---|
| Founded | 1947 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 6.5B |
| IPO Year | 2000 | 2019 |
| Metric | CRL | OBDC |
|---|---|---|
| Price | $215.32 | $12.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $205.27 | $14.44 |
| AVG Volume (30 Days) | 664.0K | ★ 3.9M |
| Earning Date | 02-18-2026 | 02-18-2026 |
| Dividend Yield | N/A | ★ 12.71% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.39 |
| Revenue | ★ $4,023,704,000.00 | $1,797,946,000.00 |
| Revenue This Year | N/A | $19.12 |
| Revenue Next Year | $1.70 | N/A |
| P/E Ratio | ★ N/A | $8.82 |
| Revenue Growth | N/A | ★ 11.43 |
| 52 Week Low | $91.86 | $11.65 |
| 52 Week High | $228.88 | $15.73 |
| Indicator | CRL | OBDC |
|---|---|---|
| Relative Strength Index (RSI) | 53.76 | 39.13 |
| Support Level | $217.57 | $12.20 |
| Resistance Level | $224.78 | $12.77 |
| Average True Range (ATR) | 7.35 | 0.24 |
| MACD | -1.33 | -0.03 |
| Stochastic Oscillator | 32.29 | 0.00 |
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Blue Owl Capital Corp is a specialty finance company and business development company (BDC) focused on providing direct lending solutions to U.S. middle-market companies. The company seeks to generate current income and, to a lesser extent, capital appreciation by targeting investment opportunities with favorable risk-adjusted returns, including senior secured, subordinated, or mezzanine loans and equity-related instruments. Its investment strategies are intended to generate favorable returns across credit cycles with an emphasis on preserving capital.